Articles

Rapid adoption of FDA-approved biosimilars is feasible, measurable, and scalable—and pharmacists should lead the charge, according to data presented at the virtual 2021 American Society of Clinical Oncology Quality Care Symposium.

Oncology Pipeline Overview: Recent Approvals and Near-Term Drugs

By Wayne Kuznar

February 2022, Vol 13, No 1 Online Only

Many innovative therapies in oncology have made it to market recently, with a wealth of agents that are currently on the verge of FDA approval.

Support Services for Patients with Cancer Must Go Beyond Simply Building a HUB

By Wayne Kuznar

February 2022, Vol 13, No 1 Online Only

The success of oncology support services developed by pharmaceutical manufacturers depends on tailoring programs that meet the needs of their specific patient populations, said panelists at a roundtable discussion on patient centricity and connectivity in oncology support and HUB services.

Preliminary Evidence for Identifying Patterns of Organ Damage in Advanced Systemic Mastocytosis Subtypes

ASH 2021 Systemic Mastocytosis Wrap-Up

Conference Correspondent

Criteria to assess presenting patterns of organ damage have not been extensively evaluated. Preliminary evidence suggests identifying these patterns could be useful in profiling organ dysfunction in avapritinib clinical trials.

Cladribine as First-Line Therapy for Indolent and Advanced Systemic Mastocytosis

ASH 2021 Systemic Mastocytosis Wrap-Up

Conference Correspondent

Cladribine has long been established as an efficient therapy in systemic mastocytosis and remains a valuable treatment option even as new therapies emerge.

Genetic Testing for Hereditary Alpha-Tryptasemia in Patients Presenting with Mast-Cell Mediator Symptoms in the Absence of Symptoms of Mastocytosis

ASH 2021 Systemic Mastocytosis Wrap-Up

Conference Correspondent

Hereditary alpha-tryptasemia may promote development of systemic mastocytosis. Screening for variations in copy number of the alpha tryptase gene may provide early evidence for diagnosis of mastocytosis.

Assessing the Potential Role of Anti-CD117 CAR T-Cells for Targeted Therapy in Advanced Systemic Mastocytosis

ASH 2021 Systemic Mastocytosis Wrap-Up

Conference Correspondent

CAR T-cell immunotherapy is highly efficient because of its ability to target specific tumor antigens. Preliminary evidence suggests that CAR T-cells directed against CD117, the KIT receptor, may emerge as a therapeutic option for advanced systemic mastocytosis.

Whole Genome Sequencing Detects Chromosomal Aberrations Associated with Systemic Mastocytosis

ASH 2021 Systemic Mastocytosis Wrap-Up

Conference Correspondent

Cytogenetic aberrations are rarely found by cytogenetics in systemic mastocytosis but are associated with advanced disease. Whole genome sequencing detects both chromosomal aberrations and non-KIT gene mutations and can be used as an alternative to cytogenetics for assessing disease risk.

Navigation Is About Value

By Sharon Gentry, MSN, RN, HON-ONN-CG, AOCN, CBCN

Videos

Sharon Gentry, MSN, RN, HON-ONN-CG, AOCN, CBCN, Program Director, Academy of Oncology Nurse & Patient Navigators (AONN+), said she attended the AVBCC Summit because oncology nurse and patient navigation is "all about value" across the cancer care continuum.

Navigators Need a Place at the Table

By Sharon Gentry, MSN, RN, HON-ONN-CG, AOCN, CBCN

Videos

We are making progress, but oncology nurse navigators need to have a louder voice in these meetings with stakeholders because, as patient advocates, they are often the keepers of patient experience, said Sharon Gentry, MSN, RN, HON-ONN-CG, AOCN, CBCN, Program Director, Academy of Oncology Nurse & Patient Navigators (AONN+).

Articles

Top Trending Articles

Stay In The Know

Articles

Page 30 of 329

Top Trending Articles

Stay In The Know

We Value Your Feedback! Tell Us How You Consume Content